Syndax Pharmaceuticals

ACRES, BSI collaborate on clinical research sites standards

Tuesday, December 13, 2016

The Alliance for Clinical Research Excellence and Safety (ACRES), in partnership with the British Standards Institution (BSI), has launched a multi-stakeholder global working party to fast-track development of standards for all aspects of site work, laying the foundation for recognizing and rewarding excellence at clinical research sites worldwide and accelerating development of safe and effective new medicines.

[Read More]

Syndax appoints Dr. Briggs Morrison CEO, Michael Metzger president and COO

Monday, June 15, 2015

Syndax Pharmaceuticals, a privately held oncology company based in Waltham, Mass., has announced that Briggs W. Morrison, M.D., is joining the company as CEO and a member of the board of directors, and Michael A. Metzger is joining the company as president and chief operating officer. Morrison joins Syndax from AstraZeneca, where he was executive vice president, global medicines development and chief medical officer. Metzger joins from Regado Biosciences, where he was president and CEO through the company’s strategic merger with Tobira Therapeutics.

[Read More]

Syndax, Merck to collaborate on immuno-oncology study

Wednesday, April 1, 2015

Syndax Pharmaceuticals, based in Waltham, Mass., and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax’s entinostat, an investigational epigenetic therapy, with Merck’s Keytruda (pembrolizumab), the first anti-PD-1 therapy approved in the U.S. The phase Ib/II study will evaluate this novel combination regimen in patients with either advanced non-small cell lung cancer (NSCLC) or melanoma. The study is expected to begin enrolling patients in the second half of 2015.

[Read More]

Neovacs forms U.S. subsidiary

Wednesday, March 25, 2015

Neovacs, a Paris-based biotechnology company focused on autoimmune and inflammatory diseases, has established a wholly-owned U.S. subsidiary, Neovacs Inc. Neovacs Inc. is headquartered in Boston and has been incorporated in Delaware.

[Read More]